Palmitoylethanolamide is a naturally occurring, fat-derived substance made in the body, sold as oral supplements and skin products, and studied mainly for pain and other symptoms. Human research offers credible but inconsistent evidence of pain relief, small studies that repeatedly found lower eye pressure, and evidence of fewer respiratory illness episodes. Over short periods, side effects are generally infrequent. Slower aging or longer life is not established. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Blood PEA | No established target; symptoms and function are tracked instead | Unsupported dosing targets are avoided |
| Kidney and liver laboratory tests | No PEA-specific optimal range; individual baseline and the laboratory's reference intervals are tracked | Contextual safety |
| Eye pressure, when treating glaucoma | Individual ophthalmologist-defined target; change from baseline is tracked | Measures the relevant endpoint |
| Inflammation markers | No PEA response target; the underlying clinical condition is tracked instead | Success judged by a laboratory value alone is avoided |
Cadence: Tolerance at one to two weeks, symptoms at four weeks, and continued benefit at eight to twelve weeks; longer use can be reassessed every three to six months. An observational framework, not a validated PEA monitoring schedule.